Novavax Introduced Combo Vaccine for COVID-19 and Flu – World Vaccine Congress

Novavax, Public domain, via Wikimedia Commons

Maryland-based vaccine maker Novavax introduced a COVID-19 booster and flu combination vaccine candidate at the World Vaccine Congress in Washington. According to their study, their protein-nanoparticle vaccine Nuvaxoid showed responses against newer variants of the SARS-CoV-2 virus (BA.1, BA.4, and BA.5 of the Omicron variant). This vaccine performed similarly to the immune response of the approved mRNA vaccines. 

The new widely spreading Omicron subvariant XB.1.5 is more advanced and the current vaccines are effective against the earlier strains rather than XB.1.5. The vaccine makers and FDA are working on an updated or next-gen COVID vaccine that could ideally target the variant. 

Source: Novavax

The combination vaccine of Novavax under investigation uses full-length, stabilized recombinant spike (rS) protein of the SARS-Co-2 virus, and wild-type recombinant Hemaggluttin (rHA) proteins from the influenza virus, as antigens. (Source: novavax.com). 

Why Combination Vaccine

Editor's Desk

+ postsBio ⮌

• Editor's Desk

  Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide
• Editor's Desk

  U.S. FDA Approves Venclexta and Acalabrutinib Combination for First-Line CLL Treatment
• Editor's Desk

  GSK Announces Breakthrough Phase III Results for Bepirovirsen, Signaling Potential “Functional Cure” for Chronic Hepatitis B
• Editor's Desk

  BiotechReality’s 2025 Review and 2026 Predictions: 2025 The Year Molecular Precision Met Global Scale & 2026: The Year of Orchestrated Biology